Afrezza sales are dismal. Don't see a success story here with a glass of water still being the preferred delivery system for type 2 diabetics.
Fair value: $2.50
p.s. Checkout $AMBS under a nickel. It offers substantially more upside than MNKD under $5.00.
Reminds me of another company that did the same thing years ago. It was called Amgen. It's my understanding that one of Amgen's co-founders is also associated with Amarantus.
Could it be that he's involved in a new attempt to fleece unsuspecting investors that will eventually end up the same as it did for the Amgen shareholders?
Someone should investigate this possibility before substantial profits occur..
.20 would make me happier.
Next thing you know they'll be claiming that Gerald's birth certificate is a forgery.
Orphan designation for the company's patented drug, MANF, for Retinitis Pigmentosa expected this week from the European Commission.
Zacks' Senior Bio-Tech Analyst rates it a buy with a valuation four times its current market cap.
$AMGN was under a dime at one point in its history.
Amarantus Bioscience - AMBS - Under a dime.
Zack's Senior Bio-Tech Analyst says it's worth four times the current market cap.
p.s. Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the company's B.O.D.